S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

PVLA Palvella Therapeutics Inc

23.94

0.00 (0.00%)

Pre Market

Last Updated: 22:39:10

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics Inc News

Form 8-K - Current report
Wednesday 5 March 2025 (3 days ago) • Edgar (US Regulatory)

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Wednesday 26 February 2025 (1 week ago) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Wednesday 19 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Tuesday 11 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Tuesday 11 February 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Saturday 18 January 2025 (2 months ago) • Edgar (US Regulatory)

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Saturday 11 January 2025 (2 months ago) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Thursday 9 January 2025 (2 months ago) • Edgar (US Regulatory)

More Palvella Therapeutics Inc News Articles

S&P ASX 300 Metals and M...

Sterling vs AUD

Australian SE All Ordina...

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions